Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801456 | 1.00 | PNMT (0.49) | PNMTPRCPTRPA1LMNATSHR | |
| Hydrochloric Acid SCHEMBL4158562 | 0.98 | PNMT (0.47) | PNMTPRCPTRPA1LMNATSHR | |
| Hydrochloric Acid SCHEMBL30319882 | 0.98 | PNMT (0.47) | PNMTPRCPTRPA1LMNATSHR | |
| SCHEMBL29609011 | 0.88 | CD44 (0.49) | PNMTTRPA1LMNATSHR | |
| SCHEMBL2355554 | 0.88 | CD44 (0.49) | PNMTTRPA1LMNATSHR | |
| Hydrochloric Acid SCHEMBL4438179 | 0.87 | CD44 (0.47) | PNMTTRPA1LMNATSHR | |
| SCHEMBL6095089 | 0.86 | TRPA1 (0.48) | TRPA1LMNATSHR | |
| Hydrochloric Acid SCHEMBL29877364 | 0.84 | TRPA1 (0.47) | TRPA1LMNATSHR | |
| Hydrochloric Acid SCHEMBL6093232 | 0.84 | TRPA1 (0.47) | TRPA1LMNATSHR | |
| SCHEMBL15704302 | 0.84 | PNMT (0.45) | PNMTPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| CN-117015404-A | Anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124102-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-08-26 | — | — | US | disclosed |
| US-7749996-B2 | Heterotricyclic metalloprotease inhibitors | Alantos Pharmaceutical Holdings, Inc. (US) | 2010-07-06 | — | — | US | disclosed |
| EP-2176252-A1 | 2, 3-DIHYDROBENZO[1, 4]DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-04-21 | — | — | EP | disclosed |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2009013390-A1 | 2, 3-DIHYDROBENZO[1, 4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009001128-A1 | 1,2-CYCL0HEXANE DICARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | PNMT 4682/4885PRCP 1340/4885TRPA1 4885/4885 |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | PNMT 1796/4885PRCP 149/4885TRPA1 4001/4885 |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | PNMT 3879/4885PRCP 2745/4885TRPA1 4308/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | PNMT 4405/4885PRCP 561/4885TRPA1 4800/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | PNMT 1796/4885PRCP 149/4885TRPA1 4001/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | PNMT 4782/4885PRCP 1311/4885TRPA1 4862/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | PNMT 4782/4885PRCP 1311/4885TRPA1 4862/4885 |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | BAX, BCL2, BCL3 | PNMT 3879/4885PRCP 2745/4885TRPA1 4308/4885 |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | PMP22, NPY2R, ADRA2C | PNMT 1000/4885PRCP 1496/4885TRPA1 513/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | PNMT 1796/4885PRCP 149/4885TRPA1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.